Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
Authors
Keywords
-
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 387, Issue 16, Pages 1445-1455
Publisher
Massachusetts Medical Society
Online
2022-10-20
DOI
10.1056/nejmoa2118828
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The humanistic burden of vitiligo: a systematic literature review of quality‐of‐life outcomes
- (2022) M. Picardo et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Vitiligo: A focus on pathogenesis and its therapeutic implications
- (2021) Christina Bergqvist et al. JOURNAL OF DERMATOLOGY
- Oral gliadin‐protected superoxide dismutase in addition to phototherapy for treating non‐segmental vitiligo: A 24‐week prospective randomized placebo‐controlled study
- (2021) E. Fontas et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials
- (2021) Hou-Ren Tsai et al. Journal of Personalized Medicine
- Psychosocial Effects of Vitiligo: A Systematic Literature Review
- (2021) Khaled Ezzedine et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial
- (2021) Iltefat Hamzavi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Vitiligo Skin T Cells Are Prone to Produce Type 1 and Type 2 Cytokines to Induce Melanocyte Dysfunction and Epidermal Inflammatory Response Through Jak Signaling
- (2021) Christina Martins et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study
- (2020) Abdallah Khemis et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- What is a successful repigmentation in vitiligo from patients’ view?
- (2020) V.S. Narayan et al. BRITISH JOURNAL OF DERMATOLOGY
- Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
- (2020) David Rosmarin et al. LANCET
- Mechanisms of melanocyte death in vitiligo
- (2020) Jianru Chen et al. MEDICINAL RESEARCH REVIEWS
- Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo
- (2019) Ji Hae Lee et al. JAMA Dermatology
- The effectiveness of topical calcineurin inhibitors comparing with topical corticosteroids in the treatment of vitiligo: a systematic review and meta-analysis
- (2019) Hua-Ching Chang et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
- (2018) Deep Joshipura et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Importance of light in the treatment of vitiligo with JAK-inhibitors
- (2017) Deep Joshipura et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- New discoveries in the pathogenesis and classification of vitiligo
- (2017) Michelle Rodrigues et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
- (2017) Brooke Rothstein et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference
- (2017) Emily Y. Gan et al. Pigment Cell & Melanoma Research
- Phototherapy for Vitiligo
- (2017) Jung Min Bae et al. JAMA Dermatology
- Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo
- (2016) X. X. Wang et al. BRITISH JOURNAL OF DERMATOLOGY
- Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients
- (2015) Claire Regazzetti et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN-γ for Autoreactive CD8+ T-Cell Accumulation in the Skin
- (2012) John E. Harris et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Acral lesions of vitiligo: why are they resistant to photochemotherapy?
- (2011) S.M. Esmat et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use
- (2010) M.S. LEWIS-JONES et al. BRITISH JOURNAL OF DERMATOLOGY
- Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients
- (2009) Jasper G. van den Boorn et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo
- (2008) G Sanclemente et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started